Heqet Therapeutics
Heqet Therapeutics is a pre-clinical stage biotech company developing non-coding RNA-based therapies for cardiovascular diseases, with a particular emphasis on acute myocardial infarction. Originating from pioneering research by Prof. Mauro Giacca, the company aims to become the standard of care for myocardial infarction induced regeneration by targeting multiple pathways via upregulation of non-coding RNAs, including microRNAs, to stimulate cardiac regeneration and repair.
Industries
Nr. of Employees
small (1-50)
Heqet Therapeutics
Via Ettore De Sonnaz, 19, 10121, Torino, Italy
Products
Preclinical microRNA-LNP therapeutic candidates for cardiac regeneration
Preclinical therapeutic candidates consisting of selected microRNAs formulated in lipid nanoparticles for localized myocardial delivery to induce cardiomyocyte proliferation and functional myocardial repair; intended indications include ST-elevation myocardial infarction (STEMI) and heart failure with reduced ejection fraction (HFrEF).
Preclinical microRNA-LNP therapeutic candidates for cardiac regeneration
Preclinical therapeutic candidates consisting of selected microRNAs formulated in lipid nanoparticles for localized myocardial delivery to induce cardiomyocyte proliferation and functional myocardial repair; intended indications include ST-elevation myocardial infarction (STEMI) and heart failure with reduced ejection fraction (HFrEF).
Services
Design and execution of preclinical efficacy and safety studies for RNA-based cardiac therapeutics in small and large animal models, including functional outcome and electrophysiology assessments.
Development and optimization of lipid nanoparticle formulations for targeted myocardial delivery of small RNA therapeutics and guidance on catheter-based administration routes.
Partnership development and joint programs with academic centers and CROs to advance RNA-based cardiac regeneration programs toward clinical development.
Design and execution of preclinical efficacy and safety studies for RNA-based cardiac therapeutics in small and large animal models, including functional outcome and electrophysiology assessments.
Development and optimization of lipid nanoparticle formulations for targeted myocardial delivery of small RNA therapeutics and guidance on catheter-based administration routes.
Partnership development and joint programs with academic centers and CROs to advance RNA-based cardiac regeneration programs toward clinical development.
Expertise Areas
- Non-coding RNA therapeutics
- Cardiac regeneration and myocardial repair
- Lipid nanoparticle formulation and targeted delivery
- Preclinical in vivo study design (rodent and large animal)
Key Technologies
- MicroRNA-based therapeutics
- Lipid nanoparticles (LNPs)
- Hippo/YAP pathway modulation
- Intracoronary infusion and endocardial injection
News & Updates
A scientific publication by Mauro Giacca discussing the regulatory pathways involved in microRNAs that induce cardiomyocyte proliferation.
A scientific publication by Mauro Giacca on microRNA therapy promoting cardiac repair in pigs after myocardial infarction.
A scientific publication by Mauro Giacca on the effects of single-dose intracardiac injection of microRNAs on cardiac function post-myocardial infarction.
A scientific publication by Mauro Giacca on screening for miRNAs that induce cardiac regeneration.
A scientific publication by Mauro Giacca discussing the regulatory pathways involved in microRNAs that induce cardiomyocyte proliferation.
A scientific publication by Mauro Giacca on microRNA therapy promoting cardiac repair in pigs after myocardial infarction.
A scientific publication by Mauro Giacca on the effects of single-dose intracardiac injection of microRNAs on cardiac function post-myocardial infarction.
A scientific publication by Mauro Giacca on screening for miRNAs that induce cardiac regeneration.